Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 167 articles:
HTML format
Text format



Single Articles


    November 2019
  1. DEL GIUDICE F, Barchetti G, De Berardinis E, Pecoraro M, et al
    Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Eur Urol. 2019 Nov 4. pii: S0302-2838(19)30757.
    PubMed     Text format     Abstract available


    October 2019
  2. YATAI KB, Tran H, Dunning MJ, Wang D, et al
    Sources of Bias Within Consensus Subtypes of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Oct 23. pii: S0302-2838(19)30760.
    PubMed     Text format    


    September 2019
  3. KETTUNEN K, Bostrom P, Taimen P
    Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://do
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30731.
    PubMed     Text format    


  4. LIU X
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016: Can Patie
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30734.
    PubMed     Text format    


  5. KRIEGMAIR MC, Rother J, Grychtol B, Theuring M, et al
    Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging.
    Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30674.
    PubMed     Text format     Abstract available


  6. KAMOUN A, Reynies A, Allory Y, Sjodahl G, et al
    A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30695.
    PubMed     Text format     Abstract available


  7. LEOW JJ, Catto JWF, Efstathiou JA, Gore JL, et al
    Quality Indicators for Bladder Cancer Services: A Collaborative Review.
    Eur Urol. 2019 Sep 25. pii: S0302-2838(19)30690.
    PubMed     Text format     Abstract available


  8. SHI MJ, Meng XY, Chen CL, Dyrskjot L, et al
    Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Can
    Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30656.
    PubMed     Text format    


    August 2019
  9. VARMA M, Delahunt B, Kwast TV
    Reply to Eva Comperat, Mahul Amin, Victor Reuter's Editorial Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. htt
    Eur Urol. 2019 Aug 29. pii: S0302-2838(19)30676.
    PubMed     Text format    


  10. YANG A, Cannataro VL, Townsend JP
    Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.
    Eur Urol. 2019 Aug 29. pii: S0302-2838(19)30662.
    PubMed     Text format    


  11. BABJUK M, Burger M, Comperat EM, Gontero P, et al
    European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30660.
    PubMed     Text format     Abstract available


  12. LU M, Zhang Y, Xiao Y
    Re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.06.016.
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30605.
    PubMed     Text format    


  13. KETTUNEN K, Bostrom PJ, Taimen P
    Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. In
    Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30610.
    PubMed     Text format    


    July 2019
  14. ELANDER NO, Hussain SA
    Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer.
    Eur Urol. 2019 Jul 26. pii: S0302-2838(19)30593.
    PubMed     Text format    


  15. VOSKUILEN CS, van der Heijden MS, van Rhijn BWG
    Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Jul 24. pii: S0302-2838(19)30543.
    PubMed     Text format    


  16. COMPERAT E, Amin M, Reuter V
    Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.05.001: Two Decades of Wor
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30541.
    PubMed     Text format    


  17. PEDERZOLI F, Bandini M, Briganti A, Plimack ER, et al
    Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.
    Eur Urol. 2019 Jul 11. pii: S0302-2838(19)30522.
    PubMed     Text format     Abstract available


    June 2019
  18. KETTUNEN K, Bostrom PJ, Lamminen T, Heinosalo T, et al
    Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells.
    Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30501.
    PubMed     Text format     Abstract available


    May 2019
  19. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Usi
    Eur Urol. 2019 May 17. pii: S0302-2838(19)30379.
    PubMed     Text format    


  20. INARRITU JM, Castellani D, Teoh JYC
    Re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol. In press. https://doi.org/10.1016/j.eururo.
    Eur Urol. 2019 May 15. pii: S0302-2838(19)30378.
    PubMed     Text format    


  21. CAO L, Yang Z, Wang B
    Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019; 75,5: 853-860.
    Eur Urol. 2019 May 10. pii: S0302-2838(19)30364.
    PubMed     Text format    


  22. VARMA M, Delahunt B, van der Kwast T
    Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question.
    Eur Urol. 2019 May 10. pii: S0302-2838(19)30362.
    PubMed     Text format     Abstract available


  23. GSCHWEND JE, Heck M
    Reply to Satoru Taguchi, Tohru Nakagawa, and Hiroshi Fukuhara's Letter to the Editor re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy:
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30346.
    PubMed     Text format    


  24. LI R, Spiess PE, Gilbert SM, Necchi A, et al
    Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2019 May 2. pii: S0302-2838(19)30344.
    PubMed     Text format    


  25. DIJKSTRA S, Wijburg CJ
    Re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71: Can the Pattern of Cancer Recurrence T
    Eur Urol. 2019;75:e137.
    PubMed     Text format    


  26. BOCHNER BH, Dalbagni G
    Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outc
    Eur Urol. 2019;75:e138-e139.
    PubMed     Text format    


  27. YANG Y, Wei X, Han P
    Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.027.
    Eur Urol. 2019 May 1. pii: S0302-2838(19)30343.
    PubMed     Text format    


  28. TAGUCHI S, Nakagawa T, Fukuhara H
    Re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604-11.
    Eur Urol. 2019 May 1. pii: S0302-2838(19)30345.
    PubMed     Text format    


    April 2019
  29. SORIA F, Gontero P
    Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2019 Apr 12. pii: S0302-2838(19)30275.
    PubMed     Text format    


  30. SAITA A, Lughezzani G, Buffi NM, Hurle R, et al
    Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging.
    Eur Urol. 2019 Apr 10. pii: S0302-2838(19)30277.
    PubMed     Text format     Abstract available


  31. SHI MJ, Meng XY, Lamy P, Banday AR, et al
    APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
    Eur Urol. 2019 Apr 8. pii: S0302-2838(19)30261.
    PubMed     Text format     Abstract available


  32. GUST KM, Shariat SF
    Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study.
    Eur Urol. 2019;75:695-696.
    PubMed     Text format    


  33. LERNER SP, Svatek RS
    What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy?
    Eur Urol. 2019;75:612-614.
    PubMed     Text format    


  34. MARKOWSKI MC, Boorjian SA, Burton JP, Hahn NM, et al
    The Microbiome and Genitourinary Cancer: A Collaborative Review.
    Eur Urol. 2019;75:637-646.
    PubMed     Text format     Abstract available


  35. ABUFARAJ M, Foerster B, Schernhammer E, Moschini M, et al
    Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.
    Eur Urol. 2019;75:649-658.
    PubMed     Text format     Abstract available


  36. KELLY JD, Tan WS, Porta N, Mostafid H, et al
    BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
    Eur Urol. 2019;75:593-601.
    PubMed     Text format     Abstract available


    March 2019
  37. UENO Y, Takeuchi M, Tamada T, Sofue K, et al
    Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study.
    Eur Urol. 2019 Mar 25. pii: S0302-2838(19)30198.
    PubMed     Text format     Abstract available


  38. MOUW KW, Miyamoto DT, Efstathiou JA
    Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.040: Towards Biomarker-Informed M
    Eur Urol. 2019 Mar 22. pii: S0302-2838(19)30195.
    PubMed     Text format    


  39. CAMPI R, Roupret M
    Re: Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-institutional Cohort Study.
    Eur Urol. 2019 Mar 14. pii: S0302-2838(19)30187.
    PubMed     Text format    


  40. GAKIS G
    Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2019 Mar 13. pii: S0302-2838(19)30181.
    PubMed     Text format    


  41. LI R, Spiess PE, Gilbert SM, Necchi A, et al
    Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30174.
    PubMed     Text format     Abstract available


  42. NARAYAN VM, Lim AH, Dinney CPN
    Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30165.
    PubMed     Text format    


  43. RIJNDERS M, van der Veldt AAM, Zuiverloon TCM, Grunberg K, et al
    PD-L1 Antibody Comparison in Urothelial Carcinoma.
    Eur Urol. 2019;75:538-540.
    PubMed     Text format    


  44. VAN DIJK N, Funt SA, Blank CU, Powles T, et al
    The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    Eur Urol. 2019;75:435-444.
    PubMed     Text format     Abstract available


    February 2019
  45. WITJES JA
    Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    Eur Urol. 2019 Feb 25. pii: S0302-2838(19)30163.
    PubMed     Text format    


  46. PICHLER R, Heidegger I
    Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.11.055.
    Eur Urol. 2019 Feb 22. pii: S0302-2838(19)30159.
    PubMed     Text format    


  47. GOLDSTEIN MR, Mascitelli L
    Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.008.
    Eur Urol. 2019 Feb 11. pii: S0302-2838(19)30093.
    PubMed     Text format    


  48. CHOUDHURY A, Hoskin PJ
    Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues.
    Eur Urol. 2019 Feb 4. pii: S0302-2838(19)30086.
    PubMed     Text format    


  49. MONTORSI F, Gandaglia G
    Re: Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, et al. Port-site Metastases After Robot-assisted Radical Cystectomy: Is There a Publication Bias? Eur Urol 2018;73:641-2.
    Eur Urol. 2019;75:e31.
    PubMed     Text format    


  50. FICARRA V, Giannarini G, Crestani A, Palumbo V, et al
    Retrosigmoid Versus Traditional Ileal Conduit for Urinary Diversion After Radical Cystectomy.
    Eur Urol. 2019;75:294-299.
    PubMed     Text format     Abstract available


    January 2019
  51. EFSTATHIOU JA, Mouw KW, Gibb EA, Liu Y, et al
    Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30012.
    PubMed     Text format     Abstract available


  52. BESSA A, Maclennan S, Enting D, Bryan R, et al
    Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method.
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30075.
    PubMed     Text format    


  53. RADZISZEWSKI P, Poletajew S
    Re: Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-G
    Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30074.
    PubMed     Text format    


  54. ZUIVERLOON TCM, Theodorescu D
    Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol. 2019 Jan 17. pii: S0302-2838(18)31024.
    PubMed     Text format    


  55. LI R, Tabayoyong WB, Guo CC, Gonzalez GMN, et al
    Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease.
    Eur Urol. 2019;75:8-10.
    PubMed     Text format     Abstract available


    December 2018
  56. VALENBERG FJPV, Hiar AM, Wallace E, Bridge JA, et al
    Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30959.
    PubMed     Text format     Abstract available


  57. TAN TZ, Rouanne M, Huang RY, Thiery JP, et al
    Reply to Pontus Eriksson and Gottfrid Sjodahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 T
    Eur Urol. 2018 Dec 5. pii: S0302-2838(18)30952.
    PubMed     Text format    


  58. ERIKSSON P, Sjodahl G
    Re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.08.0
    Eur Urol. 2018 Dec 3. pii: S0302-2838(18)30953.
    PubMed     Text format    


  59. VOGELZANG NJ
    Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity?
    Eur Urol. 2018;74:754-755.
    PubMed     Text format    


    November 2018
  60. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostat
    Eur Urol. 2018 Nov 30. pii: S0302-2838(18)30942.
    PubMed     Text format    


  61. MOSCHINI M, Zaffuto E, Mattei A, Karakiewicz PI, et al
    Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical
    Eur Urol. 2018 Nov 29. pii: S0302-2838(18)30941.
    PubMed     Text format    


  62. FIORENTINO A, Errico A, Scarcia M
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 27. pii: S0302-2838(18)30881.
    PubMed     Text format    


  63. ZAORSKY NG, Spratt DE, Blanchard P
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30882.
    PubMed     Text format    


  64. PANEBIANCO V, Barentsz J, Narumi Y, Catto JWF, et al
    Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imagi
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30720.
    PubMed     Text format    


  65. HENRIQUE R, Nunes SP, Jeronimo C
    MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges.
    Eur Urol. 2018 Nov 20. pii: S0302-2838(18)30871.
    PubMed     Text format    


  66. GOODSPEED A, Jean A, Costello JC
    A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Eur Urol. 2018 Nov 7. pii: S0302-2838(18)30835.
    PubMed     Text format     Abstract available


  67. COLOMBO R, Rocchini L, Suardi N, Benigni F, et al
    Corrigendum re "Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study" [Eur Urol 2012;62:797-802].
    Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30662.
    PubMed     Text format    


  68. NECCHI A, Messina A, Briganti A
    Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria With
    Eur Urol. 2018;74:e107-e108.
    PubMed     Text format    


    October 2018
  69. BABJUK M
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30827.
    PubMed     Text format    


  70. CHOI W, McConkey DJ
    ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers.
    Eur Urol. 2018 Oct 23. pii: S0302-2838(18)30732.
    PubMed     Text format    


  71. GSCHWEND JE, Heck MM, Lehmann J, Rubben H, et al
    Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30737.
    PubMed     Text format     Abstract available


  72. GORE JL, Wright JL
    Can We Prevent Bladder Cancer Recurrences?
    Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30749.
    PubMed     Text format    


  73. MOSCHINI M, Zaffuto E, Karakiewicz PI, Andrea DD, et al
    External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30722.
    PubMed     Text format     Abstract available


  74. WITJES JA
    Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need?
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30727.
    PubMed     Text format    


  75. GRIFFIN JL
    Devil in the Detail: Intratumour Heterogeneity and Personalised Medicine for Bladder Cancer.
    Eur Urol. 2018 Oct 3. pii: S0302-2838(18)30724.
    PubMed     Text format    


  76. PIETZAK EJ, Zabor EC, Bagrodia A, Armenia J, et al
    Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol. 2018 Oct 2. pii: S0302-2838(18)30652.
    PubMed     Text format     Abstract available


  77. YUH B, Chan K, Wilson T
    Robotic Cystectomy-Moving from Innovation to Measurable Impact.
    Eur Urol. 2018;74:472-473.
    PubMed     Text format     Abstract available


    September 2018
  78. TAN WS, Panchal A, Buckley L, Devall AJ, et al
    Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Gueri
    Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30655.
    PubMed     Text format     Abstract available


  79. ARENDS TJH, Witjes JA
    Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bac
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30647.
    PubMed     Text format    


  80. ABEYSIRI S, Richards T
    Re: Dipen J. Parekh, Isidinha M. Reis, Erik P. Castle, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial. Lancet 2018;391:2525-36:
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30664.
    PubMed     Text format    


  81. CUMBERBATCH MGK, Jubber I, Black PC, Esperto F, et al
    Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.
    Eur Urol. 2018 Sep 26. pii: S0302-2838(18)30651.
    PubMed     Text format     Abstract available


  82. WARRICK JI, Sjodahl G, Kaag M, Raman JD, et al
    Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
    Eur Urol. 2018 Sep 25. pii: S0302-2838(18)30653.
    PubMed     Text format     Abstract available


  83. TEOH JYC, Herrmann TRW, Babjuk M
    Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306.
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30657.
    PubMed     Text format    


  84. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30663.
    PubMed     Text format    


  85. GARG H, Nayak B, Singh P
    Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and Hi
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30648.
    PubMed     Text format    


  86. DYRSKJOT L
    Molecular Subtypes of Bladder Cancer: Academic Exercise or Clinical Relevance?
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30656.
    PubMed     Text format    


  87. TAN TZ, Rouanne M, Tan KT, Huang RY, et al
    Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Eur Urol. 2018 Sep 10. pii: S0302-2838(18)30619.
    PubMed     Text format     Abstract available


  88. GIANNARINI G, Crestani A, Ficarra V
    Re: Stenting Prior to Cystectomy Is an Independent Risk Factor for Upper Urinary Tract Recurrence.
    Eur Urol. 2018;74:395-396.
    PubMed     Text format    


    August 2018
  89. MOSTAFID H, Palou J, Burger M, Babjuk M, et al
    T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues.
    Eur Urol. 2018 Aug 30. pii: S0302-2838(18)30601.
    PubMed     Text format    


  90. LINARES-ESPINOS E, Sanchez-Salas R
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 22. pii: S0302-2838(18)30562.
    PubMed     Text format    


  91. GIANNARINI G, Crestani A, Ficarra V
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 20. pii: S0302-2838(18)30564.
    PubMed     Text format    


    July 2018
  92. HOVELSON DH, Udager AM, McDaniel AS, Grivas P, et al
    Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Eur Urol. 2018 Jul 19. pii: S0302-2838(18)30475.
    PubMed     Text format     Abstract available


  93. PANEBIANCO V, Barentsz J, Narumi Y, Catto J, et al
    Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging
    Eur Urol. 2018 Jul 17. pii: S0302-2838(18)30457.
    PubMed     Text format    


  94. KRANTZ D, Hartana CA, Winerdal ME, Johansson M, et al
    Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.
    Eur Urol. 2018 Jul 16. pii: S0302-2838(18)30476.
    PubMed     Text format     Abstract available


  95. ECKSTEIN M, Sikic D, Strissel PL, Erlmeier F, et al
    Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.
    Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30456.
    PubMed     Text format    


  96. SONPAVDE G, Dranitsaris G, Necchi A
    Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
    Eur Urol. 2018;74:63-65.
    PubMed     Text format    


    June 2018
  97. THOENY HC, Bellin MF, Comperat EM, Thalmann GN, et al
    Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30442.
    PubMed     Text format    


    May 2018
  98. PANEBIANCO V, Narumi Y, Altun E, Bochner BH, et al
    Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).
    Eur Urol. 2018 May 10. pii: S0302-2838(18)30335.
    PubMed     Text format     Abstract available


  99. GEYNISMAN DM, Abbosh PH, Plimack ER, Zibelman M, et al
    Chemoimmunotherapy in Metastatic Urothelial Carcinoma.
    Eur Urol. 2018;73:760-762.
    PubMed     Text format    


  100. PEEKER R
    Re: Molecular Classification of Urothelial Carcinoma: Global mRNA Classification Versus Tumour-cell Phenotype Classification.
    Eur Urol. 2018;73:809-810.
    PubMed     Text format    


  101. KAMAT AM, Li R, O'Donnell MA, Black PC, et al
    Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We There Yet? A Systematic Review.
    Eur Urol. 2018;73:738-748.
    PubMed     Text format     Abstract available


    April 2018
  102. MOSCHINI M, Sargos P
    Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy a Randomized Phase 2 Trial.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30203.
    PubMed     Text format    


  103. FABA OR, Breda A, Palou J
    Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2018 Apr 7. pii: S0302-2838(18)30243.
    PubMed     Text format    


  104. BOCHNER BH
    Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome.
    Eur Urol. 2018;73:558-559.
    PubMed     Text format    


    March 2018
  105. SARFATY M, Hall PS, Chan KKW, Virik K, et al
    Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Eur Urol. 2018 Mar 22. pii: S0302-2838(18)30182.
    PubMed     Text format     Abstract available


  106. CUMBERBATCH MGK, Foerster B, Catto JWF, Kamat AM, et al
    Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol. 2018 Mar 6. pii: S0302-2838(18)30121.
    PubMed     Text format     Abstract available


    February 2018
  107. EL-ACHKAR A, Kassouf W
    Re: Propensity Score Analysis of Radical Cystectomy Versus Bladder-sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Eur Urol. 2018 Feb 14. pii: S0302-2838(18)30088.
    PubMed     Text format    


  108. NECCHI A, Anichini A, Sonpavde G
    Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.
    Eur Urol. 2018;73:153-155.
    PubMed     Text format    


  109. WILSON SS, Crawford ED
    Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.
    Eur Urol. 2018;73:233-235.
    PubMed     Text format    


  110. SZABADOS B, van Dijk N, Tang YZ, van der Heijden MS, et al
    Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
    Eur Urol. 2018;73:149-152.
    PubMed     Text format     Abstract available


    January 2018
  111. LEE B, Kim JH
    Re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e13-e14.
    PubMed     Text format    


    December 2017
  112. SAITO R, Kobayashi T, Ogawa O
    Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31042.
    PubMed     Text format    


  113. PANG KH, Noon AP
    Re: Radical Cystectomy (Bladder Removal) Against Intravesical BCG Immunotherapy for High-risk Non-muscle Invasive Bladder Cancer (BRAVO): A Protocol for a Randomised Controlled Feasibility Study.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31039.
    PubMed     Text format    


  114. OOSTERLINCK W, Decaestecker K
    Re: Active Surveillance for Low-risk Nonmuscle Invasive Bladder Cancer (NMIBC): a Confirmatory and Resource Consumption Study from Bladder Cancer Italian Active Surveillance (BIAS) Project.
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31018.
    PubMed     Text format    


  115. CUMBERBATCH MG, Catto JWF
    Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31007.
    PubMed     Text format    


    November 2017
  116. ODDENS JR, de Reijke TM
    The Current State of Predicting Response on Bacillus Calmette-Guerin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action.
    Eur Urol. 2017 Nov 30. pii: S0302-2838(17)31006.
    PubMed     Text format    


  117. CHOI W, McConkey D
    Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in The Cancer Genome Atl
    Eur Urol. 2017 Nov 23. pii: S0302-2838(17)30979.
    PubMed     Text format    


  118. LINSCOTT JA, Smith AB, Sammon JD
    Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30971.
    PubMed     Text format    


  119. ABUFARAJ M, Dalbagni G, Daneshmand S, Horenblas S, et al
    The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30840.
    PubMed     Text format     Abstract available


    October 2017
  120. MAIA MC, Grivas P, Agarwal N, Pal SK, et al
    Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30902.
    PubMed     Text format    


    September 2017
  121. OHNO Y
    Re: Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Sep 26. pii: S0302-2838(17)30780.
    PubMed     Text format    


  122. BIRKENKAMP-DEMTRODER K, Christensen E, Nordentoft I, Knudsen M, et al
    Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30775.
    PubMed     Text format     Abstract available


    August 2017
  123. LEOW JJ, Cole AP, Seisen T, Bellmunt J, et al
    Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
    Eur Urol. 2017 Aug 9. pii: S0302-2838(17)30640.
    PubMed     Text format     Abstract available


    July 2017
  124. BOSSCHIETER J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, et al
    Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30538.
    PubMed     Text format     Abstract available


    June 2017
  125. SAFIRI S, Ayubi E
    Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Expe
    Eur Urol. 2017 Jun 22. pii: S0302-2838(17)30503.
    PubMed     Text format    


  126. GIACALONE NJ, Niemierko A, Shipley WU, Efstathiou JA, et al
    Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: A
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30502.
    PubMed     Text format    


  127. BOSSCHIETER J, Vis AN, van der Poel HG, Moonen LM, et al
    Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
    Eur Urol. 2017 Jun 12. pii: S0302-2838(17)30494.
    PubMed     Text format     Abstract available


  128. POWLES T, Gomez de Liano A, Ackerman C
    Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First
    Eur Urol. 2017 Jun 9. pii: S0302-2838(17)30453.
    PubMed     Text format    


  129. D'ANDREA D, Shariat SF
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    Eur Urol. 2017 Jun 6. pii: S0302-2838(17)30481.
    PubMed     Text format    


  130. DYRSKJOT L, Reinert T, Algaba F, Christensen E, et al
    Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30475.
    PubMed     Text format     Abstract available


  131. PIETZAK EJ, Bagrodia A, Cha EK, Drill EN, et al
    Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30466.
    PubMed     Text format     Abstract available


  132. CHEVALIER MF, Bohner P, Pieraerts C, Lhermitte B, et al
    Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
    Eur Urol. 2017;71:854-857.
    PubMed     Text format     Abstract available


  133. WANG L, Sustic T, Leite de Oliveira R, Lieftink C, et al
    A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Eur Urol. 2017;71:858-862.
    PubMed     Text format     Abstract available


    May 2017
  134. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30455.
    PubMed     Text format    


  135. SEISEN T, Cole AP, Trinh QD
    Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol. In press. http://doi.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30411.
    PubMed     Text format    


  136. KULKARNI GS, Klaassen Z
    Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?
    Eur Urol. 2017 May 5. pii: S0302-2838(17)30338.
    PubMed     Text format    


  137. BABJUK M
    Bladder Cancer in the Elderly.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30326.
    PubMed     Text format    


  138. FONTEYNE V, Ost P, Bellmunt J, Droz JP, et al
    Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30230.
    PubMed     Text format     Abstract available


  139. COLLINS JW, Hosseini A, Adding C, Nyberg T, et al
    Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group.
    Eur Urol. 2017;71:723-726.
    PubMed     Text format     Abstract available


    April 2017
  140. SOUKUP V, Capoun O, Cohen D, Hernandez V, et al
    Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel
    Eur Urol. 2017 Apr 27. pii: S0302-2838(17)30323.
    PubMed     Text format     Abstract available


  141. GALSKY MD, Sfakianos JP, Ferket BS
    Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30292.
    PubMed     Text format    


  142. BLACK PC
    Seeking the Molecular Truth in Bladder Cancer: Biology=Genomex(Transcriptome)2.
    Eur Urol. 2017 Apr 17. pii: S0302-2838(17)30286.
    PubMed     Text format    


  143. SEILER R, Oo HZ, Tortora D, Clausen TM, et al
    An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30232.
    PubMed     Text format     Abstract available


  144. SEILER R, Ashab HA, Erho N, van Rhijn BW, et al
    Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Eur Urol. 2017 Apr 5. pii: S0302-2838(17)30251.
    PubMed     Text format     Abstract available


  145. GAKIS G, Black PC, Bochner BH, Boorjian SA, et al
    Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.
    Eur Urol. 2017;71:545-557.
    PubMed     Text format     Abstract available


    March 2017
  146. CHOI W, Ochoa A, McConkey DJ, Aine M, et al
    Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30175.
    PubMed     Text format     Abstract available


  147. BOKARICA P, Hrkac A, Gilja I
    Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.
    Eur Urol. 2017 Mar 6. pii: S0302-2838(17)30126.
    PubMed     Text format    


  148. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    PubMed     Text format     Abstract available


  149. BABJUK M, Bohle A, Burger M, Capoun O, et al
    EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Eur Urol. 2017;71:447-461.
    PubMed     Text format     Abstract available


    February 2017
  150. MAY M, Lebentrau S, Brookman-May SD
    Re: Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30107.
    PubMed     Text format    


  151. COTTE J, Roupret M
    Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer.
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30106.
    PubMed     Text format    


  152. MARQUES M, Real FX
    PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30087.
    PubMed     Text format    


    January 2017
  153. ROTH B
    Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30012.
    PubMed     Text format    


  154. GIACALONE NJ, Shipley WU, Clayman RH, Niemierko A, et al
    Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Eur Urol. 2017 Jan 9. pii: S0302-2838(16)30924.
    PubMed     Text format     Abstract available


  155. DE VERE WHITE R
    Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia.
    Eur Urol. 2017 Jan 7. pii: S0302-2838(16)30921.
    PubMed     Text format    


  156. CHRISTENSEN E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, et al
    Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Eur Urol. 2017 Jan 6. pii: S0302-2838(16)30920.
    PubMed     Text format     Abstract available


    December 2016
  157. SELINSKI S, Gerullis H, Otto T, Roth E, et al
    Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30904.
    PubMed     Text format    


    October 2016
  158. LIEDBERG F, Jancke G, Sorenby A, Kannisto P, et al
    Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
    Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30713.
    PubMed     Text format     Abstract available


  159. NECCHI A, Giardiello D, Mariani L
    Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30684.
    PubMed     Text format    


    September 2016
  160. LUO HL, Chen YT, Cheng YT, Chiang PH, et al
    Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Can
    Eur Urol. 2016 Sep 26. pii: S0302-2838(16)30663.
    PubMed     Text format    


  161. SEISEN T, Babjuk M, Roupret M
    Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for
    Eur Urol. 2016 Sep 22. pii: S0302-2838(16)30662.
    PubMed     Text format    


    April 2016
  162. PICKARD R
    Is Robot-assisted Cystectomy Better than Open?--Nearing an Answer after a Decade of Use.
    Eur Urol. 2016;69:622-3.
    PubMed     Text format    


  163. KHAN MS, Gan C, Ahmed K, Ismail AF, et al
    A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2016;69:613-21.
    PubMed     Text format     Abstract available


    March 2016
  164. HAMILTON-REEVES JM, Bechtel MD, Hand LK, Schleper A, et al
    Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial.
    Eur Urol. 2016;69:389-92.
    PubMed     Text format     Abstract available


    February 2016
  165. SATKUNASIVAM R, Santomauro M, Chopra S, Plotner E, et al
    Robotic Intracorporeal Orthotopic Neobladder: Urodynamic Outcomes, Urinary Function, and Health-related Quality of Life.
    Eur Urol. 2016;69:247-53.
    PubMed     Text format     Abstract available


  166. KAMAT AM, Briggman J, Urbauer DL, Svatek R, et al
    Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin.
    Eur Urol. 2016;69:197-200.
    PubMed     Text format     Abstract available


  167. SYLVESTER RJ, Oosterlinck W, Holmang S, Sydes MR, et al
    Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carci
    Eur Urol. 2016;69:231-44.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: